6th Cancer Cachexia Conference 
August 27-29, 2021

Final Program – now virtual!
Bridging Molecular Advances to Clinical Care

Please access sessions via the Whova app: https://ccc2021.events.whova.com

Until October 15, 2021, all recordings are available to registered attendees in the Whova app (with consent of the presenter)
(see the Resources section, or visit each session to access).


Times correspond to US East Coast Time Zone. 

Continuing Medical Education –
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. 
This activity was approved by the Canadian Association of Medical Oncologists for a maximum of 20 hours.


Updated: August 26, 2021

Friday, August 27, 2021

Clinical Advances in Cancer Cachexia

Session A: Outcome Measures for Cancer Cachexia

Lindsey Anderson, PhD – University of Washington, USA
Richard Dunne, MD – University of Rochester, USA

8:10 am

Introductory Remarks

Denis C. Guttridge, PhD
Medical University of South Carolina, USA

Jonathan D. Licht, MD
Director, University of Florida Health Cancer Center, USA

Ray DuBois, MD, PhD
Director, MUSC Hollings Cancer Center

Kelvin Lee, MD
Director, IU Simon Comprehensive Cancer Center

8:30 am David Currow, MD
University of Technology Sydney, Australia
“What have we learnt from clinical trials in cancer cachexia?”
9:00 am Jann Arends, MD
University of Freiburg, Germany
“Clinical practice guidelines on cancer cachexia”
9:30 am Jorge Nieva, MD
University of Southern California, USA
“Karnofsky revisited – Measuring performance status in the digital age”
10:00 am Break

Session B: Clinical Trial Results

Gillian Gresham, PhD, Cedars-Sinai Medical Center, USA
Jose Trevino, MD, Virginia Commonwealth University, USA

10:30 am Marie Fallon, MD
University of Edinburgh, UK
“Phenotyping of patients in clinical trials of cancer cachexia”
11:00 am Tora Solheim, MD, PhD
St. Olavs Hospital, Trondheim University Hospital, Norway
“Why do we need a complex intervention in cancer cachexia?”
11:30 am Stein Kaasa, MD, PhD
University of Oslo, Norway
“Cancer cachexia classification anno 2022: A common system for research and clinical practice?”
  Selected Short Talks
12:00 pm Ishan Roy, MD
Northwestern University, USA
“Six minute walk test improvement but not grip strength correlates with gains in functional independence in cancer patients with cachexia”
12:15 pm Rebekah Patton, PhD 
University of Edinburgh, UK
“A prospective characterization of cancer cachexia in patients with incurable cancer”
12:30 pm Break

Session C: Conversations with Patients and Caregivers

R. Thomas Jagoe, MD – McGill University, Canada
Martin Kochanczyk, PhD – Pattern Bioscience, USA

1:30–2:30 pm


Richard Dunne, MD
University of Rochester, USA

Medical oncologist assessing physical activity

Monica P. Parmar, RN, PhD(c)
McGill University, Canada

Nurse in cancer nutrition rehabilitation

Eric Roeland, MD
Oregon Health & Science University, USA

Medical oncologist treating symptoms of cancer therapies

Christina Van Der Borch, P.Dt
McGill University, Canada

Dietitian in cancer nutrition rehabilitation

2:30-4:00 pm Break
Session 1
Keynote Address

Denis C. Guttridge, PhD – Medical University of South Carolina, USA
Teresa Zimmers, PhD – Indiana University, USA

4:00 pm Kenneth C.H. Fearon Keynote Lectureship
Bette J Caan, PhD
Kaiser Permanente, USA
"Muscle wasting in non-metastatic cancer: Advances in our understanding, assessment and treatment"
  Cutting Edge Science in Cancer Cachexia
Junior investigators chosen from submitted abstracts
5:00 pm Miriam Ferrer Gonzalez – Cold Spring Harbor, USA
“Early neutrophilia marked by aerobic glycolysis sustains host metabolism and delays cancer cachexia”
5:05 pm Gillian Gresham, PhD – Cedars-Sinai Medical Center, USA
“Remote monitoring of biometric data and patient-reported outcomes in patients with cancer cachexia during the COVID-19 pandemic”
5:10 pm Michelle Law, PhD – Baylor College of Medicine, USA
“Cardiac myocyte intrinsic contractility and calcium handling deficits underlie heart organ dysfunction in murine cancer cachexia”
5:15 pm Ja Young Kim-Muller, PhD – Pfizer Global, USA
“GDF15 neutralization improves muscle function and physical performance in a mouse model of cancer cachexia”
5:20 pm Benjamin Pryce, PhD – Medical University of South Carolina, USA
“Local inflammation in cancer cachexia derives from multiple cell populations in the muscle microenvironment under the control of NF-kB”
5:25 pm Yichi Zhang – University of Texas Southwestern, USA
“Molecular mechanisms defining cancer cachexia-induced muscle atrophy”
5:30-6:30 pm Social Hour

Back to top ...

Saturday, August 28, 2021

Session 2
Metabolic Dysfunction in Cancer Cachexia

Emidio Pistilli, PhD – West Virginia University, USA
Erin Talbert, PhD – University of Iowa, USA

8:30 am Pankaj K. Singh, PhD
University of Nebraska Medical Center, USA
"Molecular regulation of oxidative damage in skeletal muscle in pancreatic cancer"
9:00 am Stephan Herzig, PhD
Helmholtz Diabetes and Cancer Center, Germany
"Organ-specific metabolic programs in cancer cachexia"
  Selected Short Talks
9:30 am Lykke Sylow, PhD 
University of Copenhagen, Denmark
“AMPK protects against cancer-associated muscle mass loss and metabolic perturbations”
9:45 am Aneesha Dasgupta, PhD 
Mayo Clinic, USA
“Anti-cachectic regular analysis reveals novel anti-tumorigenic mechanisms of 3-MA via the inhibition of Perp in pancreatic cancer”
10:30 am Break
Session 3
Mechanisms of Skeletal Muscle Wasting: Myofiber

Gabriela Salim de Castro, PhD – University of São Paulo, Brazil
Derek Hall, PhD – University of Ottawa, Canada

11:00 am Paul Gregorevic, PhD
University of Melbourne, Australia
“Exploring and targeting new mechanisms implicated in muscle wasting associated with cancer cachexia”
11:30 am David Glass, MD
Regeneron, USA
“Overlap between mechanisms of Covid19-induced ARDS and cachexia”
12:00 pm Andrew Judge, PhD
University of Florida, USA
“Mechanisms of cachexia initiation”
12:30 pm Break
1:30-4:00 pm Poster Viewing
Session 4
Nutrition Imbalance and Strategies in Cancer Cachexia

Trude R. Balstad, PhD – Norwegian University of Science and Technology - NTNU, Norway
Rishi Jain, MD – Fox Chase Cancer Center, USA

4:00 pm Klaske van Norren, PhD
Wageningen University, Netherlands
"The gut brain axis in the cancer-related anorexia-cachexia syndrome"
4:30 pm Cristina Cintra Gomes Marcondes, PhD
University of Campinas, Brazil
"Nutrition as a coadjuvant therapy in cachexia preclinical models"
  Selected Short Talks
5:00 pm Tor Erik Rusten, PhD
University of Oslo, Norway
"Autophagy mediates organ wasting and nutrient mobilization for tumor growth in Drosophila melanogaster"
5:15 pm Marc Beltrà, PhD
University of Torino, Italy
"Niacin supplement restores NAD+ levels and counteracts muscle wasting in cancer and chemotherapy-driven cachexia"
5:30 pm End of program day

Back to top ...

Sunday, August 29, 2021

Session 5
Biological Variables in Cancer Cachexia

Andrea Bonetto, PhD – Indiana University, USA
Sarah Judge, PhD – University of Florida, USA

8:30 am Vickie Baracos, PhD
University of Alberta, Canada
"Sexual dimorphism in clinical cancer cachexia: fact or fiction?"
9:00 am James Carson, PhD
University of Tennessee Health Science Center, USA
“Understanding female systemic and skeletal muscle metabolic dysfunction with cancer cachexia and chemotherapy in mice”
  Selected Short Talks
9:30 am Dario Coletti, PhD 
Sapienza University of Rome, Italy
"Displaced myonuclei in cancer cachexia suggest altered innervation"
9:45 am Pauline Morigny, PhD 
Helmholtz Diabetes and Cancer Center, Germany
"Association of circulating PLA2G7 levels with cancer cachexia and assessment of darpladib as a therapy"
10:00 am Break
Session 6
Next Generation Researchers in Cancer Cachexia

Marcus Goncalves, MD, PhD – Weill Cornell Medical College, USA
Melissa Puppa, PhD – The University of Memphis, USA

To promote upcoming and young faculty researchers: Speakers chosen from submitted applications.

10:30 am Lindsey Anderson, PhD
University of Washington, USA
“Whole-body and adipose tissue metabolic phenotype in cancer patients”
10:45 am Shinpei Kawaoka, PhD
Kyoto University, Japan
“Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase”
11:00 am Young-Mee Kim, PhD
University of Illinois at Chicago, USA
“Downregulation of PGC1-alpha in the skeletal muscle endothelium mediates cancer cachexia by compromising vascular barrier integrity”
11:15 am Fabrizio Pin, PhD
Indiana University School of Medicine, USA
“Mitochondria-targeted agent MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice”
11:30 am Joseph Rupert, PhD
Indiana University School of Medicine, USA
“Deletion of PKC-theta in mice with PDAC is associated with increased survival, increased in vivo muscle force production, decreased muscle wasting, and reduced expression of Pdk4 in skeletal muscle”
11:45 am Wouter van de Worp
Maastricht University, Netherlands
“Automated quantification of tumor volume and characterization of cachexia in a novel orthotopic lung cancer mouse model”
12:00 pm Break
Session 7
Mechanisms of Muscle Wasting: Muscle Microenvironment

Fabio Penna, PhD – University of Torino, Italy
Roberta Sartori, PhD – University of Padova, Italy

1:30 pm Michael Rudnicki, PhD
University of Ottawa, Canada
"Molecular regulation of stem cell function"
2:00 pm Denis Guttridge, PhD
Medical University of South Carolina, USA
“The interplay between the inflammatory cascade and muscle atrophy in cancer cachexia”
2:30 pm Jerome Feige, PhD
Nestle, Switzerland
"Targeting muscle stem cells through nutrition in aging and cancer cachexia"
3:00 pm Break
Session 8
Therapy-Induced Muscle Dysfunction and Wasting

Danna Breen, PhD – Pfizer Inc., USA
Ashley Smuder, PhD – University of Florida, USA

3:30 pm Andrea Bonetto, PhD
Indiana University, USA
"Novel insights into the mechanisms of chemotherapy-induced muscle wasting"
4:00 pm Chris Coss, PhD
The Ohio State University, USA
"Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans"
  Selected Short Talks
4:30 pm Russell Hepple, PhD
University of Florida, USA
“Doxorubicin toxicity in skeletal muscle involves mitochondrial permeability transition”
4:40 pm Ashley Smuder, PhD
University of Florida, USA
"Mitochondrial dysfunction in chemotherapy-related myotoxicity"
4:50 pm Nicolas Collao
University of Ottawa, Canada
“Radiation therapy reduces skeletal muscle fibro-adipogenic progenitors and induces a profibrotic phenotype”
5:00 pm Closing Remarks

Back to top ...